A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

NCT00504556 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1146

Enrollment

INDUSTRY

Sponsor class

Conditions

Atrial Fibrillation
Thromboembolism

Interventions

DRUG: Edoxaban (DU-176b)
DRUG: Edoxaban (DU-176b)
DRUG: Edoxaban (DU-176b)
DRUG: Edoxaban (DU-176b)
DRUG: warfarin

Sponsor

Daiichi Sankyo